Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High response, survival rates with ponatinib/hCVAD in Ph-positive ALL

Publish date:: January 8, 2020

Key clinical point: Ponatinib plus chemotherapy appears superior to chemotherapy with older tyrosine kinase inhibitors.

Major finding: The 5-year overall survival rate was 74%.

Study details: A prospective single-arm trial in 86 adults with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Disclosures: The study was sponsored by MD Anderson with support from the National Cancer Institute. Dr. Short reported consulting for AstraZeneca, honoraria from Amgen, and consulting and receiving research funding from Takeda Oncology.

Citation:

Short NJ et al. ASH 2019, Abstract 283.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,